WUHAN, HUBEI PROVINCE, CHINA, February 15, 2026 /EINPresswire.com/ — In the complex landscape of life science research, selecting the right cellular model is a ...
Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat dose Clinical entry planned H2 2026 CAMBRIDGE, Mass., ...
A groundbreaking study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes, or B cells, in the progression of Type 1 diabetes (T1D). B cells are immune cells ...
Let’s say it’s 2036, and scientists are working on a new class of drugs. These medications are mirror-image versions of the molecules your body uses to fight disease. Their big advantage is that ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results